Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 32Neoplasms, Plasma Cell 6Recurrence 4Lymphoma 4Leukemia 3Hodgkin Disease 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Plasma Cell 2Hematologic Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Participation 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

liposomal doxorubicin 1TKN732 1Melphalan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Patient Participation × liposomal doxorubicin × Plasma cell × Clear all
NCT00985907 2020-06-17

DMV

University of California, San Francisco

Phase 1/2 Terminated
13 enrolled 8 charts
Plasma cell

Multiple Myeloma, Patient Participation, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡